<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="apt15779-tbl-0005" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 4B</label>
 <caption>
  <p>Interactions with IBD medications</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" rowspan="2" valign="bottom" colspan="1">COVID‐19 treatments</th>
    <th align="left" colspan="8" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Interactions with IBD treatments</th>
   </tr>
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Corticosteroids</underline>
     </p>
     <p>Methylprednisolone, Prednisolone, Budesonide, Beclomethasone, Hydrocortisone*#:</p>
     <p>Metabolised by CYP3A4, CYP3A5*, CYP3A7*</p>
     <p>Substrate: P‐glycoprotein</p>
     <p>#Not clinically relevant</p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Thiopurines</underline> (azathioprine/ mercaptopurine)
     </p>
     <p>Metabolised by: TMPT, HGPRT, XO</p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Methotrexate</underline>
     </p>
     <p>Transported into the cell by: Reduced folate carrier 1</p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Tacrolimus</underline>
     </p>
     <p>Inhibits: CYP3A4 (weak)</p>
     <p>Metabolised by CYP3A4</p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Ciclosporin</underline>
     </p>
     <p>Metabolised by CYP3A4</p>
     <p>Inhibits: CYP3A4 (moderate),P‐glycoprotein</p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Tofacitinib</underline>
     </p>
     <p>Metabolised by CYP3A4 (major) CYP2C19 (minor)</p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">5ASA</underline>
     </p>
    </th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Biologics</underline>
     </p>
     <p>Adalimumab</p>
     <p>Infliximab</p>
     <p>Golimumab</p>
     <p>Vedolizumab</p>
     <p>Ustekinumab</p>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Remdesivir</bold>
     </p>
     <p>
      <bold>(GS‐5734)</bold>
     </p>
     <p>Adults ≥40 kg: Daily IV dose over 30 min. Day 1: 200 mg</p>
     <p>Day 2‐10: 100 mg</p>
     <p>Paed &lt;40 kg: Daily IV dose over 30min.</p>
     <p>Day 1: 5 mg/kg</p>
     <p>Day 2‐10: 2.5 mg/kg</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Lopinavir/Ritonavir (Kaltera) (400 mg/100 mg)</bold>
     </p>
     <p>400 mg/100 mg twice daily for 14 days</p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>Crushing tablet ↓ absorption ≅ 45%
      <xref rid="apt15779-bib-0133" ref-type="ref">
       <sup>133</sup>
      </xref>. Use oral liquid (42.4% alcohol and 15.3% propylene glycol)
     </p>
     <p>Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and disulfiram</p>
     <p>Absorbed in jejunum: NG ok; NJ may ↓ effect</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ 
      <bold>Methylprednisolone:</bold> Consider 50% dose reduction 
      <xref rid="apt15779-bib-0124" ref-type="ref">
       <sup>124</sup>
      </xref>.
     </p>
     <p>↑ 
      <bold>Prednisolone:</bold>
     </p>
     <p>↓ plasma cortisol (level if appropriate)</p>
     <p>↑ 
      <bold>Budesonide:</bold>
     </p>
     <p>10‐20% absorbed
      <xref rid="apt15779-bib-0134" ref-type="ref">
       <sup>134</sup>
      </xref>. AUC may ↑ 6.5 fold 
      <xref rid="apt15779-bib-0024" ref-type="ref">
       <sup>24</sup>
      </xref> Consider changing steroid agent or taking budesonide an hour before lopinavir/ritonavir
      <xref rid="apt15779-bib-0124" ref-type="ref">
       <sup>124</sup>
      </xref>
     </p>
     <p>↑
      <bold>Beclomethasone:</bold>
     </p>
     <p>Despite low bioavailability, increased absorption may occur, monitor for effect
      <xref rid="apt15779-bib-0069" ref-type="ref">
       <sup>69</sup>
      </xref>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ Tacrolimus levels: perform levels, consider clinical need and cease</p>
     <p>↑ QT prolongation risk– consider baseline and follow up ECG</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ Ciclosporin levels: monitor levels, consider clinical need and dose reduction</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑Tofacitinib</p>
     <p>consider clinical need and cease. If necessary, use lowest dose tofacitinib possible</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Chloroquine</bold>
     </p>
     <p>
      <bold>/ Hydroxychloroquine</bold>
     </p>
     <p>200 mg three times a day for 10 days</p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑</p>
     <p>myelosuppression risk. Recommend ceasing thiopurine in acute severe infection</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑</p>
     <p>myelosuppression risk. Recommend ceasing methotrexate in acute severe infection</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ risk of QT‐interval prolongation. consider baseline and follow up ECG</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ ciclosporin levels, perform levels if appropriate</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>May ↑ tofacitinib, clinical significance unknown.</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <bold>Interferon beta</bold>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>May ↑ corticosteroid levels, clinical significance unknown, monitor.</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>May ↑ ciclosporin levels, clinical significance unknown, monitor levels</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>May ↑ tofacitinib, clinical significance unknown, monitor. Consider lower dose where appropriate</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Ribavirin</bold>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>Do not crush –known teratogen.</p>
     <p>Contact hospital pharmacy for solution compounded from capsules or (SAS) product availability</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ risk of thiopurine induced myelosuppression</p>
     <p>Cease thiopurine</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ risk myelosuppression</p>
     <p>Cease methotrexate</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Favipiravir</bold>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Atazanavir</bold>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>Requires pH &lt;4. Avoid antacids 2 hours before and 1 hour after.</p>
     <p>Food ↑ bioavailability</p>
     <p>Absorbed in jejunum: NG ok; NJ may ↓ effect</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ 
      <bold>Methylprednisolone:</bold> Consider 50% dose reduction 
      <xref rid="apt15779-bib-0124" ref-type="ref">
       <sup>124</sup>
      </xref>.
     </p>
     <p>↑ 
      <bold>Prednisolone:</bold>
     </p>
     <p>↓ plasma cortisol (level if appropriate)</p>
     <p>↑ 
      <bold>Budesonide:</bold>
     </p>
     <p>10‐20% absorbed
      <xref rid="apt15779-bib-0134" ref-type="ref">
       <sup>134</sup>
      </xref>. AUC may ↑ 6.5 fold 
      <sup>24</sup> Consider changing steroid agent or taking budesonide an hour before lopinavir/ritonavir
      <xref rid="apt15779-bib-0124" ref-type="ref">
       <sup>124</sup>
      </xref>
     </p>
     <p>↑
      <bold>Beclomethasone:</bold>
     </p>
     <p>Despite low bioavailability, increased absorption may occur, monitor for effect
      <xref rid="apt15779-bib-0069" ref-type="ref">
       <sup>69</sup>
      </xref>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ ciclosporin and ↑ atazanavir.</p>
     <p>Do not co‐administer.</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>↑ tofacitinib, recommend ceasing tofacitinib</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Nitazoxanide (prodrug)</bold>
     </p>
     <p>
      <bold>(active metabolite: tizoxanide)</bold>
     </p>
     <p>
      <bold>May be dispersible or crushed– check brand</bold>
     </p>
     <p>Take with food ‐ increases bioavailability by 50%.</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <bold>Tocilizumab (IL‐6 monoclonal antibody)</bold>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <inline-graphic xlink:href="APT-9999-na-g001.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="apt15779-ntgp-0030">
  <fn id="apt15779-note-0030">
   <p>
    <inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Can be crushed; 
    <inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Can open capsule; 
    <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Do not crush; 
    <inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Liquid product available; No clinically significant interaction expected; 
    <inline-graphic xlink:href="APT-9999-na-g002.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Interaction, monitor and dose adjust as required; 
    <inline-graphic xlink:href="APT-9999-na-g003.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Do not administer due to interaction and clinical setting
   </p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
